Document is current
Any future updates will be listed below
-
Authors
Jonas, Jost B. https://orcid.org/0000-0003-2972-5227
Panda-Jonas, Songhomitra
Xu, Jie https://orcid.org/0000-0002-2039-7055
Jonas, Rahul A. https://orcid.org/0000-0002-5389-3047
Wang, Ya Xing https://orcid.org/0000-0003-2749-7793
-
Funding
Funding for this research was provided by:
National Natural Science Foundation
- License Information
-
More Information
Article History
Received: 25 June 2025
Revised: 16 December 2025
Accepted: 23 January 2026
First Online: 9 February 2026
Competing interests
: SP-J, RAJ, JBJ: European patent EP 3 271 392, JP 2021-119187, and U.S. Patent No. US 12,024,557 B2: “Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; European patent application 23196899.1”. EGFR Antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of RPE cells.
